File Download
 
 
Supplementary

Conference Paper: Prediction of post-hepatectomy HCC recurrence by circulating cancer stem cells
  • Basic View
  • Metadata View
  • XML View
TitlePrediction of post-hepatectomy HCC recurrence by circulating cancer stem cells
 
AuthorsYang, ZF
Fan, ST
Ho, DWY
Yu, WC
Lau, CK
Ng, MNP
Lam, CY
 
Issue Date2009
 
PublisherInternational Liver Cancer Association.
 
CitationThe 3rd Annual Conference of the International Liver Cancer Association (ILCA 2009), Milan, Italy, 4-6 September 2009. [How to Cite?]
 
AbstractBACKGROUND: Recurrence of HCC frequently occurs within the first year after hepatectomy. Intrahepatic recurrence is due to new tumorogenic foci, whereas extrahepatic recurrence is probably related to circulating tumor cells shed from the primary tumor prior to hepatectomy. Since cancer stem cells (CSCs) are more likely to initiate tumor growth than mature cancer cells, high level of CSCs may be a hint for HCC recurrence. OBJECTIVES: This study aims to investigate whether circulating CSCs can predict recurrence of HCC after hepatectomy. METHODS: Multi-colour flow cytometry was used to detect the number of circulating CSCs (CD45-CD90+CD44+) in the peripheral circulation of 53 patients of HCC one day before curative hepatectomy. The patients were monitored by CT or MRI for recurrence every three months. RESULTS: Twenty-three patients had recurrence (intrahepatic and/or extrahepatic) after a median follow-up period of 20 months (range 2 – 48 months). The patients with recurrence had a higher level of circulating CSCs than those without (0.04% vs. 0%, p = 0.001). Patients with >0.01% circulating CSCs had a higher 2-year recurrence rate (78.2% vs. 24%, p = 0.0001) and a lower 2-year overall survival rate (55% vs. 88.8%, p = 0.0136) than those with ≤0.01% circulating CSCs. Extrahepatic recurrence occurred in the lung (8), bone (2), diaphragm (1), lymph nodes (3), adrenal gland (1) and spleen (2) in 14 patients. Sensitivity, specificity and accuracy of circulating CSCs >0.01% predicting extrahepatic recurrence were 86%, 67% and 72% respectively. Only 2 of 25 patients with circulating CSCs <0.01% developed extrahepatic recurrence, and none of the 15 patients with CSCs undetectable developed extrahepatic recurrence. CONCLUSION: Circulating CSCs predicted post-hepatectomy recurrence of HCC with high accuracy. Circulating CSCs may be the target of eradication in the prevention of extrahepatic metastasis of HCC after hepatectomy. REFERENCES: Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ Cancer Stem Cells in Human Liver Cancer. Cancer Cell 2008; 13: 153-166.
 
DescriptionOral Communications: No. 0-009
 
DC FieldValue
dc.contributor.authorYang, ZF
 
dc.contributor.authorFan, ST
 
dc.contributor.authorHo, DWY
 
dc.contributor.authorYu, WC
 
dc.contributor.authorLau, CK
 
dc.contributor.authorNg, MNP
 
dc.contributor.authorLam, CY
 
dc.date.accessioned2010-09-26T00:35:20Z
 
dc.date.available2010-09-26T00:35:20Z
 
dc.date.issued2009
 
dc.description.abstractBACKGROUND: Recurrence of HCC frequently occurs within the first year after hepatectomy. Intrahepatic recurrence is due to new tumorogenic foci, whereas extrahepatic recurrence is probably related to circulating tumor cells shed from the primary tumor prior to hepatectomy. Since cancer stem cells (CSCs) are more likely to initiate tumor growth than mature cancer cells, high level of CSCs may be a hint for HCC recurrence. OBJECTIVES: This study aims to investigate whether circulating CSCs can predict recurrence of HCC after hepatectomy. METHODS: Multi-colour flow cytometry was used to detect the number of circulating CSCs (CD45-CD90+CD44+) in the peripheral circulation of 53 patients of HCC one day before curative hepatectomy. The patients were monitored by CT or MRI for recurrence every three months. RESULTS: Twenty-three patients had recurrence (intrahepatic and/or extrahepatic) after a median follow-up period of 20 months (range 2 – 48 months). The patients with recurrence had a higher level of circulating CSCs than those without (0.04% vs. 0%, p = 0.001). Patients with >0.01% circulating CSCs had a higher 2-year recurrence rate (78.2% vs. 24%, p = 0.0001) and a lower 2-year overall survival rate (55% vs. 88.8%, p = 0.0136) than those with ≤0.01% circulating CSCs. Extrahepatic recurrence occurred in the lung (8), bone (2), diaphragm (1), lymph nodes (3), adrenal gland (1) and spleen (2) in 14 patients. Sensitivity, specificity and accuracy of circulating CSCs >0.01% predicting extrahepatic recurrence were 86%, 67% and 72% respectively. Only 2 of 25 patients with circulating CSCs <0.01% developed extrahepatic recurrence, and none of the 15 patients with CSCs undetectable developed extrahepatic recurrence. CONCLUSION: Circulating CSCs predicted post-hepatectomy recurrence of HCC with high accuracy. Circulating CSCs may be the target of eradication in the prevention of extrahepatic metastasis of HCC after hepatectomy. REFERENCES: Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ Cancer Stem Cells in Human Liver Cancer. Cancer Cell 2008; 13: 153-166.
 
dc.descriptionOral Communications: No. 0-009
 
dc.description.otherThe 3rd Annual Conference of the International Liver Cancer Association (ILCA 2009), Milan, Italy, 4-6 September 2009.
 
dc.identifier.citationThe 3rd Annual Conference of the International Liver Cancer Association (ILCA 2009), Milan, Italy, 4-6 September 2009. [How to Cite?]
 
dc.identifier.hkuros162006
 
dc.identifier.urihttp://hdl.handle.net/10722/108335
 
dc.languageeng
 
dc.publisherInternational Liver Cancer Association.
 
dc.relation.ispartofAnnual Conference of the International Liver Cancer Association
 
dc.titlePrediction of post-hepatectomy HCC recurrence by circulating cancer stem cells
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Yang, ZF</contributor.author>
<contributor.author>Fan, ST</contributor.author>
<contributor.author>Ho, DWY</contributor.author>
<contributor.author>Yu, WC</contributor.author>
<contributor.author>Lau, CK</contributor.author>
<contributor.author>Ng, MNP</contributor.author>
<contributor.author>Lam, CY</contributor.author>
<date.accessioned>2010-09-26T00:35:20Z</date.accessioned>
<date.available>2010-09-26T00:35:20Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>The 3rd Annual Conference of the International Liver Cancer Association (ILCA 2009), Milan, Italy, 4-6 September 2009.</identifier.citation>
<identifier.uri>http://hdl.handle.net/10722/108335</identifier.uri>
<description>Oral Communications: No. 0-009</description>
<description.abstract>BACKGROUND: Recurrence of HCC frequently occurs within the first year after hepatectomy. Intrahepatic recurrence is due to new tumorogenic foci, whereas extrahepatic recurrence is probably related to circulating tumor cells shed from the primary tumor prior to hepatectomy. Since cancer stem cells (CSCs) are more likely to initiate tumor growth than mature cancer cells, high level of CSCs may be a hint for HCC recurrence. OBJECTIVES: This study aims to investigate whether circulating CSCs can predict recurrence of HCC after hepatectomy. METHODS: Multi-colour flow cytometry was used to detect the number of circulating CSCs (CD45-CD90+CD44+) in the peripheral circulation of 53 patients of HCC one day before curative hepatectomy. The patients were monitored by CT or MRI for recurrence every three months. RESULTS: Twenty-three patients had recurrence (intrahepatic and/or extrahepatic) after a median follow-up period of 20 months (range 2 &#8211; 48 months). The patients with recurrence had a higher level of circulating CSCs than those without (0.04% vs. 0%, p = 0.001). Patients with &gt;0.01% circulating CSCs had a higher 2-year recurrence rate (78.2% vs. 24%, p = 0.0001) and a lower 2-year overall survival rate (55% vs. 88.8%, p = 0.0136) than those with &#8804;0.01% circulating CSCs. Extrahepatic recurrence occurred in the lung (8), bone (2), diaphragm (1), lymph nodes (3), adrenal gland (1) and spleen (2) in 14 patients. Sensitivity, specificity and accuracy of circulating CSCs &gt;0.01% predicting extrahepatic recurrence were 86%, 67% and 72% respectively. Only 2 of 25 patients with circulating CSCs &lt;0.01% developed extrahepatic recurrence, and none of the 15 patients with CSCs undetectable developed extrahepatic recurrence. CONCLUSION: Circulating CSCs predicted post-hepatectomy recurrence of HCC with high accuracy. Circulating CSCs may be the target of eradication in the prevention of extrahepatic metastasis of HCC after hepatectomy. REFERENCES: Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ Cancer Stem Cells in Human Liver Cancer. Cancer Cell 2008; 13: 153-166.</description.abstract>
<language>eng</language>
<publisher>International Liver Cancer Association.</publisher>
<relation.ispartof>Annual Conference of the International Liver Cancer Association</relation.ispartof>
<title>Prediction of post-hepatectomy HCC recurrence by circulating cancer stem cells</title>
<type>Conference_Paper</type>
<identifier.hkuros>162006</identifier.hkuros>
<description.other>The 3rd Annual Conference of the International Liver Cancer Association (ILCA 2009), Milan, Italy, 4-6 September 2009.</description.other>
</item>